Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in Vivo

Nucleic Acid Therapeutics

Volumn 22, Issue 1, 2012, Pages 40-48

  Şalva, Emine ^a,b   Kabasakal, Levent ^a   Eren, Fatih ^a   Özkan, Naziye ^b   Çakalaǧaoǧlu, Fulya ^c   Akbuǧa, Jülide ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Pathology Laboratory   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CHITOSAN; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857198814     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2011.0312     Document Type: Article

References (52)

1. AHMED, F., RAGHAVA, G.P.S. (2011). Designing of highly effective complementary and mismatch siRNAs for silencing a gene. PLoS ONE. 6, 1-8.
2. BERGERS, G., SONG, S., MEYER-MORSE, N.M., BERGSLAND, E., HANAHAN, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Investig. 111, 1287-95. (Pubitemid 36554699)
3. BOLAT, F., KAYASELÇUK, F., NURSAL, T.Z., ÇAKALAG AOG̈LU F. et al., (2006). Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J. Exp. Clin. Cancer Res. 25, 365-72. (Pubitemid 44763728)
4. CHANG, C.I., LEE, T.Y., DUA, P., KIM, S., LI, C.J., LEE, D. (2011). Long double-stranded RNA-mediated RNA interference and immunostimulation: Long interfering double-stranded RNA as a potent anticancer therapeutics. Nucleic Acid Ther. 21, 149-155.
5. CHEN, Z., VARNEY, M.L, BACKORA, M.W, COWAN, K., SOLHEIM, J.C., TALMAGE, J.E., SINGH, R.K. (2005). Downregulation of VEGF-C expression using siRNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res. 65, 9004-9011. (Pubitemid 41377392)
6. CHOI, Y.S., LEE, J.Y., SUH, J.S., KWON. Y.M., LEE, S.J., CHUNG, J.K., LEE, D.S., YANG, V.C., CHUNG, C.P., PARK, Y.J. (2010). The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 31, 1429-1443.
7. DASS, C.R., CHOONG, P.F.M. (2008). The use of chitosan formulations in cancer therapy. J Microencapsul. 25, 275-279. (Pubitemid 351935685)
8. DETMAR, M. (2000). Tumor angiogenesis. J. Investig. Dermatol. Symp. Proc. 5, 20-3. (Pubitemid 32044085)
9. DONOVAN, E.A., KUMMAR, S. (2006). Targeting VEGF in cancer therapy. Curr. Probl. Cancer 30, 7-32.
10. FERRARA, N. (2004). Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9, 2-10. (Pubitemid 38747842)
11. GERETTI, E., SHIMIZU, A., KLAGSBRUN, M. (2008). Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11, 31-39.
12. HARISH PRASHANTH, K.V., THARANATHAN, R.N. (2005). Depolymerized products of chitosan as potent inhibitors of tumor-induced angiogenesis. Biochem. Biophys. Acta. 1722, 22-29. (Pubitemid 40222401)
13. HASEGAWA, M.,YAGI, K., IWAKAWA, S., HIRAI, M. (2001). Chitosan induces apoptosis via caspase-3 activation in bladder tumor cells. Jpn. J. Cancer Res. 92, 459-466. (Pubitemid 32427783)
14. HOWARD, K.A., RAHBEK, U.L., LIU, X., DAMGAARD, C.K., GLUD, S.Z., ANDERSEN, M.Ø., HOVGAARD, M.B., SCHMITZ, A., NYENGAARD, J.R., BESENBACHER, F., KJEMS, J. (2006). RNA intereference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system, Mol. Ther. 14, 476-84. (Pubitemid 44296092)
15. HOWARD, K.A., PALUDAN, S.R., BEHLKE, M.A., BESENBACHER, F., DELEURAN, B., KJEMS, J. (2009). Chitosan/siRNA nanoparticle-mediated TNF-a knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther. 17, 162-168.
16. JUDGE, A.D., SOOD, V., SHAW, J.R., FANG, D., MCCLINTOCK, K., MACLACHLAN, I. (2005). Sequencedependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462. (Pubitemid 41724921)
17. KIM, B., TANG, Q., BISWAS, P.S., XU, J., SCHIFFLERES, R.M., XIE, F.Y., ANSARI, A.M., SCARIA, P.V., WOODLE, M.C., LU, P., ROUSE, B.T. (2004). Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Am. J. Pathol. 165, 2177-85.
18. KIM, S.H., JEONG, J.H., LEE, S.H., KIM, S.W., PARK, T.G. (2006). PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Rel. 116, 123-129. (Pubitemid 44854271)
19. KIM, S.H., JEONG, J.H., LEE, S.H., KIM, S.W., PARK, T.G. (2008). Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Rel. 129, 107-116.
20. KIM, S.S., GARG, H., JOSHI, A., MANJUNATH, N. (2009). Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med. 15, 491-500.
21. KIM, W.J., CHANG, C.W., LEE, M., KIM, S.W. (2007). Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J. Control. Release 118, 357-363. (Pubitemid 46441547)
22. LEE, S.H., KIM, S.H., PARK, T.G. (2007). Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 357, 511-516. (Pubitemid 46603160)
23. LU, P.Y., XIE, F.Y., WOODLE, M.C. (2005). Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol. Med. 11, 104-113. (Pubitemid 40348987)
24. MA, Z., LI, J., HE, F., WILSON, A., PITT, B., LI, S. (2005). Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330, 755-759. (Pubitemid 40462151)
25. MAO, S., SUN, W., KISSEL, T. (2010). Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Del. Rev. 62, 12-27.
26. MARTIN, S.E., CAPLEN, N.J. (2006). Mismatched siRNAs downregulate mRNAs as a function of target site location. FEBS Letters 580, 3694-3698. (Pubitemid 43922361)
27. MATSUMOTO, G., KUSHIBIKI, T., KINOSHITA, Y., LEE, U., OMI, Y., KUBOTA, E., TABATA, Y. (2006). Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci. 97, 313-321.
28. MCMAHON, G. (2000). VEGF receptor signaling in tumor angiogenesis. The Oncologist 5, 3-10. (Pubitemid 30225450)
29. MERYET-FIGUIERES, M., RESINA, S., LAVIGNE, C., BARLOVATZ-MEIMON, G., LEBLEU, B., THIERRY, A.R. (2007). Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range. Biochimie. 89, 1228-33. (Pubitemid 47505270)
30. MURATA, N., TAKASHIMA, Y., TOYOSHIMA, K., YAMAMOTO, M., OKADA, H. (2008). Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Rel. 126, 246-54.
31. NAITO, Y.,YAMADA, T.,UI-TEI, K., MORISHITA, S., SAIGO, K. (2004). siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference Nucleic Acids Res. 32, W124-129. (Pubitemid 38997313)
32. OH, Y-K., PARK, T.G. (2009). siRNA delivery system for cancer treatment. Adv. Drug Del. Rev. 61, 850-862.
33. QIN, C.Q., DU, Y.M.;, XIAO, L., GAO, X.H., ZHOU, J.L., LIU, H.L. 2002. Effect of molecular weight and structure on antitumor activity of oxidized chitosan. Wuhan Univ. J. Nat. Sci. 7, 231-236.
34. REICH, S.J., FOSNOT, J., KUROKI, A., TANG, W., YANG, X., MAGUEIRA, A.M. et al. (2003). siRNA targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-6. (Pubitemid 38097589)
35. REYNOLDS, A., ANDERSON, E.M., VERMEULEN, A., FEDOROV, Y., ROBINSON, K., LEAKE, D., KARPILOW, J., MARSHALL W.S., KHVOROVA, A. (2006). Induction of the interferon response by siRNA is cell type-and duplex length-dependent. RNA. 12, 988-993. (Pubitemid 43788117)
36. ROBINSON, C.J., STRINGER, S.E. (2001). The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853-65. (Pubitemid 32273121)
37. ŞALVA, E., AKBUG̈A, J. (2010a). In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines. Die Pharmazie. 65, 896-903.
38. ŞALVA, E., KABASAKAL, L., EREN, F., ÇAKALAG AOG̈LU, F., OZKAN, N., AKBUG A, J. (2010b). Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma. Oligonucleotides 20, 183-190.
39. SCHIFFELERS, R.M., MIXSON, A.J., ANSARI, A.M., MARCEL, F., TANG, Q., ZHOUC, Q., XU, J., MOLEMAD, G., LU, P.Y., SCARIA, P.V., STORM, G., WOODLE, M.C. (2005). Transporting silence:Design of carriers for siRNA to angiogenic endothelium. J. Control. Release 109, 5-14. (Pubitemid 41737248)
40. SCHIFFLERS, R.M., ANSARI, A., XU, J., ZHOU, Q., TANG, Q., STORM, G., MOLEMA, G., SCARIA, P., WOODLE, M.C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, 19, e149.
41. SCHMIDT, M., VOELKER, H-U., KAPP, M., DIETL, J., KAMMERER, U. (2008). Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with nodenegative tumour stage. Anticancer Res. 28, 1719-1724. (Pubitemid 351892949)
42. SCHMITZ, V., VILANUEVA, H., RASKOPF, E., HILBERT, T., BARAJAS, M., DZIENISOWICS, C., GORSCHLÜ TER, M., STREHL, J., RABE, C., SAUERBRUCH, T., PRIETO, J., CASELMANN, W.H., QIAN, C. (2006). Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther. 13, 1198-1205. (Pubitemid 44184713)
43. SHIBUYA, M. (1995). Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67, 281-316.
44. SUTTON, D., KIM, S., SHUAI, X., LESKOV, K., MARQUES, J.T., WILLIAMS, B.R.G., BOOTHMAN, D.A., GAO, J. (2006). Efficient suppression of secretory clusterin levels by polymersiRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int. J. Nanomedicine 1, 155-162.
45. TAKEI, Y.,KADOMATSU, K., YUZAWA, Y., MATSUO, S., MURAMATSU, T. (2004). A small interfering RNA targeting VEGF as cancer therapeutics. Cancer Res. 64, 3365-3370. (Pubitemid 38657905)
46. THOMPSON, H.J., ADLAKHA, H. (1991). Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 51, 3411-3415.
47. TREECK, O., KINDZORRA, I., PAUSER, K., ORTMANN, O. (2005). Expression of icb-1 gene is interferon-gamma inducible in breast and ovarian cancer cell lines and affects the IFN-g response of SK-OV-3 ovarian cancer cells. Cytokine. 32, 137-142. (Pubitemid 41681786)
48. TURHAL, N.S., DANE, F., DEDE, F., et al., (2004). 99m-Tc- MDPScintimammography in the evaluation of breast masses or tumor angiogenesis. Anticancer Res. 24, 1999-2006. (Pubitemid 38954624)
49. XIE, F.E.A. (2004). Delivering siRNA to animal disease models for validation of novel drug targets in vivo. PharmaGenomics July/August, 28-31.
50. YIN, J.Q., GAO, J., SHAO, R., TIAN, W.N., WANG, J., WAN, Y. (2003). siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J. Exp. Ther. Oncol. 3, 194-204. (Pubitemid 37214797)
51. ZHANG, W., YANG, H., KONG, X., MOHAPATRA, S., SAN JUAN-VERGARA, H., HELLERMANN, G., BEHERA, S., SINGAM, R., LOCKEY, R.F., MOHAPATRA, S.S. (2005). Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 11, 56-62. (Pubitemid 40215838)
52. ZHANG, Z., SUN, P., LIU J., YAN, J., LIU, Y., YU, L., WANG X., YAN, Q. (2008). Suppression of FUT1/FUT4 expression by siRNAinhibits tumor growth. Biochim. Biophys. Acta 1783, 287-296.